BR0114595A - Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t - Google Patents

Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t

Info

Publication number
BR0114595A
BR0114595A BR0114595-9A BR0114595A BR0114595A BR 0114595 A BR0114595 A BR 0114595A BR 0114595 A BR0114595 A BR 0114595A BR 0114595 A BR0114595 A BR 0114595A
Authority
BR
Brazil
Prior art keywords
thymus
cell disorder
treat
signals
sex steroid
Prior art date
Application number
BR0114595-9A
Other languages
English (en)
Inventor
Richard Lennox Boyd
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash filed Critical Univ Monash
Publication of BR0114595A publication Critical patent/BR0114595A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"USO DE UM COMPOSTO QUE ROMPE ESTERóIDE SEXUAL QUE SINALIZA PARA O TIMO NO TRATAMENTO DE UM DISTúRBIO DE CéLULAS T". A presente invenção está relacionada a um método para tratamento de um distúrbio de células T em um indivíduo, que envolve o rompimento de esteróide sexual que sinaliza para o timo e a introdução de medula óssea ou células tronco hematopoiéticas (HSC) no indivíduo.
BR0114595-9A 2000-10-13 2001-10-15 Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t BR0114595A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
PCT/AU2001/001291 WO2002030435A1 (en) 2000-10-13 2001-10-15 Treatment of t cell disorders

Publications (1)

Publication Number Publication Date
BR0114595A true BR0114595A (pt) 2003-09-16

Family

ID=3824803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114595-9A BR0114595A (pt) 2000-10-13 2001-10-15 Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t

Country Status (15)

Country Link
US (3) US20030017153A1 (pt)
EP (1) EP1333845A4 (pt)
JP (1) JP2004509979A (pt)
KR (1) KR20030060912A (pt)
CN (1) CN1529607A (pt)
AP (1) AP2003002785A0 (pt)
AU (2) AUPR074500A0 (pt)
BR (1) BR0114595A (pt)
CA (1) CA2425815A1 (pt)
EA (1) EA005573B1 (pt)
IL (1) IL155433A0 (pt)
NZ (1) NZ525508A (pt)
OA (1) OA12525A (pt)
WO (1) WO2002030435A1 (pt)
ZA (1) ZA200302931B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
WO2009046877A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a histrelin and leuprolide as therapeutic agents
AU2008297908A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
CN108884460B (zh) * 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
EP3571214A1 (en) * 2017-01-20 2019-11-27 Immune System Regulation Holding AB Novel compounds (immunorhelins- intracellular infections)
WO2018134370A1 (en) 2017-01-20 2018-07-26 Immune System Regulation Holding Ab Novel compounds (immunorhelins)
CN110381977A (zh) 2017-01-20 2019-10-25 免疫系统调节控股有限公司 已知化合物的治疗细胞内感染的新用途
AU2018225391A1 (en) 2017-02-22 2019-10-03 ISR Immune System Regulation Holding AB (publ) Gonadotropin-releasing hormones for use as adjuvant immunotherapeutics

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2238700B1 (pt) * 1973-07-24 1977-10-14 Takeda Chemical Industries Ltd
AT347054B (de) * 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
JPS5726506B2 (pt) * 1974-03-08 1982-06-04
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
FR2249677B1 (pt) * 1973-11-01 1978-07-28 Wellcome Found
JPS50142563A (pt) * 1974-04-26 1975-11-17
NL7505590A (nl) * 1974-05-18 1975-11-20 Hoechst Ag Werkwijze voor het bereiden van peptiden met lh-rh/fsh-rh-werking.
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4049805A (en) * 1975-09-30 1977-09-20 Akzona Incorporated Steroidal erythropoietic agents and therapeutic compositions and methods
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4089946A (en) * 1976-06-07 1978-05-16 American Home Products Corporation Claudogenic-interceptive nonapeptides
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
DE2905502C2 (de) * 1979-02-14 1982-07-15 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von LH-RH bzw. LH-RH-Analoga und Pyroglutamyl-N↑i↑m↑-dinitrophenyl-histidin
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5003011A (en) * 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4656247A (en) * 1985-04-26 1987-04-07 Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-QA1 6-LHRH
US4642332A (en) * 1985-04-26 1987-02-10 The Board Of Regents, The University Of Texas System Effective hormonal peptides: D-3-Pal6 -LHRH
US4775361A (en) * 1986-04-10 1988-10-04 The General Hospital Corporation Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
US4992421A (en) * 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5258492A (en) * 1988-10-21 1993-11-02 The Administrators Of The Tulane Educational Fund LHRH analogues with cytotoxic moieties at the sixth position
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5144019A (en) * 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
WO1993009815A1 (en) * 1991-11-22 1993-05-27 The General Hospital Corporation Specific tolerance in transplantation
ATE215375T1 (de) * 1992-01-08 2002-04-15 Gen Hospital Corp Induzierte toleranz gegen transplantate
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5658564A (en) * 1992-02-19 1997-08-19 The General Hospital Corporation Xenograft thymus
US5643252A (en) * 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5658892A (en) * 1993-01-15 1997-08-19 The General Hospital Corporation Compound delivery using high-pressure impulse transients
US5614502A (en) * 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
CN1127527A (zh) * 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
WO1995005843A1 (en) * 1993-08-25 1995-03-02 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
US6251100B1 (en) * 1993-09-24 2001-06-26 Transmedica International, Inc. Laser assisted topical anesthetic permeation
JPH07166906A (ja) * 1993-12-14 1995-06-27 Nissan Motor Co Ltd 燃料カットと点火時期変更による加速スリップ制御装置
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
GB9409985D0 (en) * 1994-05-18 1994-07-06 Medical Res Council Vaccine against mycobacterial infections
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1997003684A1 (en) * 1995-07-21 1997-02-06 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US6030833A (en) * 1995-08-04 2000-02-29 The General Hospital Transgenic swine and swine cells having human HLA genes
WO1997006809A1 (en) * 1995-08-21 1997-02-27 Cytrx Corporation Compositions and methods for growth promotion
US5658822A (en) * 1996-03-29 1997-08-19 Vanguard International Semiconductor Corporation Locos method with double polysilicon/silicon nitride spacer
US5741706A (en) * 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
EP0957980A4 (en) * 1996-11-27 2000-03-29 Gen Hospital Corp DELIVERY OF COMPOUNDS BY MEANS OF IMPULSE TRANSIENT PHENOMENES
US5985892A (en) * 1998-04-02 1999-11-16 Merck & Co., Ltd. Antagonists of gonadotropin releasing hormone
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040013641A1 (en) * 1999-04-15 2004-01-22 Monash University Disease prevention by reactivation of the thymus
US20040018180A1 (en) * 1999-04-15 2004-01-29 Monash University Stimulation of thymus for vaccination development
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050043245A1 (en) * 2003-08-11 2005-02-24 Siler -Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in the immune system

Also Published As

Publication number Publication date
OA12525A (en) 2006-05-31
US20040132179A1 (en) 2004-07-08
EP1333845A1 (en) 2003-08-13
JP2004509979A (ja) 2004-04-02
IL155433A0 (en) 2003-11-23
WO2002030435A1 (en) 2002-04-18
EP1333845A4 (en) 2006-05-31
ZA200302931B (en) 2004-07-14
KR20030060912A (ko) 2003-07-16
EA005573B1 (ru) 2005-04-28
AUPR074500A0 (en) 2000-11-09
EA200300461A1 (ru) 2003-10-30
CA2425815A1 (en) 2002-04-18
AU9527001A (en) 2002-04-22
AP2003002785A0 (en) 2003-06-30
CN1529607A (zh) 2004-09-15
NZ525508A (en) 2004-10-29
US20030017153A1 (en) 2003-01-23
US20060188521A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
BR0114595A (pt) Uso de um composto que rompe esteróide sexual que sinaliza para o timo no tratamento de um distúrbio de células t
ATE268782T1 (de) Zusammensetzungen zur wundheilung
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
EA200000563A1 (ru) Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
BR0207722A (pt) Material compósito de enxerto de medula óssea, método de preparação do mesmo, e, kit para a preparação do mesmo
BR9916162A (pt) Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
DE60020529D1 (de) Antikörper zur krebsbehandlung und -diagnose
EP1955700A3 (en) Therapeutic treatment of androgen receptor driven conditions
BR0202278A (pt) Dispositivos e processos para a colheita de células
DE69731843D1 (de) Medizinische vorrichtung zum anbringen von feststoffen
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
DE59807248D1 (de) Implantatkörper
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
MXPA03010634A (es) Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
IL123001A0 (en) Analgesic from snake venom
GB9903598D0 (en) Connective tissue healing
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
AP2000001907A0 (en) Crystalline form of paroxetine.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NORWOOD IMMUNOLOGY LTD. (AU)

Free format text: TRANSFERIDO DE: MONASH UNIVERSITY

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.